Core Viewpoint - Doximity Inc (NYSE:DOCS) is facing significant stock price volatility, with recent analyst ratings reflecting mixed sentiments about its future performance [1][2][3][4][6] Stock Performance - Doximity's stock opened at $23.69 after closing at $33.32, with the last traded price at $25.50, indicating a notable decline [2] - The current stock price is $27.73, down 16.78% from a previous high of $85.21 over the past year, with a trading range between $23.66 and $27.88 [4][6] - The trading volume today reached 22.18 million shares, suggesting strong investor interest despite the price fluctuations [5] Analyst Ratings - Canaccord Genuity set a price target of $34 for DOCS, indicating a potential upside of 22.61% from its current price [1] - Wall Street Zen downgraded DOCS from "buy" to "hold," while Weiss Ratings maintained a "hold (c+)" rating [2] - Conversely, Wells Fargo upgraded DOCS to "overweight" with a target price of $55.00, and both the Royal Bank Of Canada and Needham and Company LLC upgraded to "moderate buy" [3][6] Market Capitalization - Doximity's market capitalization is approximately $5.2 billion, reflecting its position in the healthcare technology sector [5]

Core Viewpoint - Doximity, Inc. (NYSE:DOCS) is recognized as a promising growth stock, with analysts highlighting its potential amidst increasing competition in healthcare AI tools, particularly following OpenAI's recent entry into the sector [1]. Group 1: Analyst Ratings and Price Targets - Raymond James reaffirmed a 'Strong Buy' rating on Doximity, Inc. with a price target of $65, indicating confidence in the company's growth potential [1]. - The firm maintained a 'Strong Buy' rating on December 29, 2025, after a meeting with Co-founder and CEO Jeff Tangney, suggesting ongoing positive sentiment towards the company [2]. Group 2: Company Performance and Market Position - Analysts believe that Doximity's engagement is set to accelerate, providing a "durable" revenue growth driver over time, which may not be fully recognized by investors [3]. - Doximity's EBITDA margins are expected to expand further from the current 55%, indicating strong financial health and operational efficiency [3]. - The company's "physicians-first ethos" is viewed as a structural moat that differentiates it from competitors, suggesting a competitive advantage in the market [3]. Group 3: Company Overview - Doximity, Inc. is a California-based digital platform for medical professionals, founded in 2010, serving a diverse customer base including physicians, medical students, pharmaceutical manufacturers, and healthcare systems [4].

Core Viewpoint - Doximity, Inc. (NYSE:DOCS) is currently viewed as an expensive stock with disappointing recent performance, leading to a recommendation against buying it at this time [1]. Company Overview - Doximity operates a digital platform that provides medical professionals with tools for collaboration, career management, research updates, documentation, and virtual patient care [1]. Recent Performance - The stock experienced a less than 1% increase since Jim Cramer's comments were aired, indicating a lack of strong market confidence [1]. Analyst Commentary - Jim Cramer expressed that Doximity had a "bad miss" in its recent quarter, which was unexpected for a high-growth company, leading to a negative outlook on the stock [1].

Core Insights - The integration of artificial intelligence (AI) in healthcare is creating new tech-driven innovators, with Tempus AI and Doximity emerging as key players in the AI health tech space [1][2] Tempus AI - Tempus AI focuses on AI-driven precision medicine, particularly in oncology and chronic disease management [2] - The company reported a 35.8% year-over-year revenue growth in Q4 2024, with gross profit rising by 49.7%, indicating improved operational leverage [3] - Tempus AI's Data and Services business achieved a 140% net revenue retention rate and has $940 million in remaining contract value, which management plans to reinvest in technology and talent [3] - Recent acquisitions of Deep 6 AI and Ambry Genetics expanded Tempus AI's clinical footprint to over 750 sites and 30 million patients, enhancing its precision medicine platform [4] - Although Q4 adjusted EBITDA was negative $7.8 million, it showed a $27.3 million year-over-year improvement, with expectations of reaching $5 million in positive adjusted EBITDA [5] - The Zacks Consensus Estimate suggests a 63% improvement in Tempus AI's loss per share for 2025 compared to 2024 [11] Doximity - Doximity reported a 25% year-over-year revenue increase in Q3 fiscal 2025, exceeding guidance by 10%, and raised full-year revenue expectations by $28 million [6] - Adjusted EBITDA reached a record $102 million with a 61% margin, up from 54% the previous year, indicating a scalable business model [6] - User engagement metrics are strong, with over 1 million prescribers on the news feed and a 60% quarter-over-quarter increase in AI usage [7] - Doximity is positioned to outpace the market with expected revenue growth of 13% in Q4 and 19% for the full year [8] - The Zacks Consensus Estimate implies a 37.9% improvement in Doximity's EPS for fiscal 2025 compared to the previous fiscal [12] Stock Performance & Valuation - Over the past three months, Tempus AI's stock has increased by 24.6%, while Doximity's stock has risen by 3.7%. However, Doximity has seen a 99.3% increase over the past year compared to Tempus AI's 0.1% rise [9] - Tempus AI trades at a forward price-to-sales (P/S) ratio of 5.24, below its one-year median of 8.49, while Doximity's forward sales multiple is 15.29, above its median of 14.39 [13] - Doximity has an average brokerage recommendation of 2.20, indicating a "Buy," while Tempus AI has a recommendation of 2.24, indicating a "Hold" [14][17] Investment Outlook - Doximity is considered a more stable and financially sound investment opportunity, with strong profitability, margins, and user engagement [20] - Tempus AI, while rapidly growing, is still in the investment phase and has yet to report positive earnings, making it less attractive for risk-averse investors [21]